

August 1, 2019

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)

In regards to the Announcement by Dr. Masayo Takahashi

It was announced that Dr. Masayo Takahashi, who led the laboratory for retinal regeneration at the RIKEN center for biosystems dynamics research, left her position as a project leader at RIKEN as of July 31, 2019.

HEALIOS K.K. (“Healios”) is granted the patent and know-how license by RIKEN providing it with exclusive worldwide rights to commercialize regenerative medicine products containing RPE cells derived from pluripotent stem cells, including iPS cells, as an active component.

The joint development between Healios and Sumitomo Dainippon Pharma Co., Ltd. in Japan based on this patent has not changed. The collaborative research project with the laboratory for retinal regeneration at the RIKEN center for biosystems dynamics research has already been completed. Further, the special advisor agreement with Dr. Takahashi has also already been completed.

It is not expected that the retirement of Dr. Takahashi from RIKEN and her assumption as CEO of Vision Care will have any impact on Healios’ business.

End of document